Ravi Venkat Bellamkonda

Ravi Venkat Bellamkonda

Auto-generated profile, based on publicly available information

Ravi Venkat Bellamkonda

Duke University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NMNassir Mokarram
Nassir Mokarram
KDKyle Dymanus
Kyle Dymanus
ASAkhil Srinivasan
Akhil Srinivasan
JLJohnathan G. Lyon
Johnathan G. Lyon
JTJohn Tipton
John Tipton
RBRavi V. Bellamkonda
Ravi V. Bellamkonda
Significance: Annually, more than 250,000 Americans suffer from a peripheral nerve injury, which results in a loss of function and a compromised quality of life. The current clinical gold standard to bridge long, nonhealing nerve gaps, the autograft, has several drawbacks. Therefore, there is a clear and urgent unmet clinical need for an alternative approach that can match or exceed autograft performance. Here we investigated the regenerative effect of fractalkine, a chemokine that preferentially recruits reparative monocytes in the synthetic nerve conduit. Our method of bridging gaps enhanced axonal regeneration and muscle reinnervation and showed results comparable to those observed in autografts.

1 May 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
JLJohnathan G. Lyon
Johnathan G. Lyon
NMNassir Mokarram
Nassir Mokarram
TSTarun Saxena
Tarun Saxena
SCSheridan L. Carroll
Sheridan L. Carroll
RBRavi V. Bellamkonda
Ravi V. Bellamkonda
Malignant brain tumors represent one of the most devastating forms of cancer with abject survival rates that have not changed in the past 60years. This is partly because the brain is a critical organ, and poses unique anatomical, physiological, and immunological barriers. The unique interplay of these barriers also provides an opportunity for creative engineering solutions. Cancer immunotherapy, a means of harnessing the host immune system for anti-tumor efficacy, is becoming a standard approach for treating many cancers. However, its use in brain tumors is not widespread. This review discusses the current approaches, and hurdles to these approaches in treating brain tumors, with a focus on immunotherapies. We identify critical barriers to immunoengineering brain tumor therapies and discuss possible solutions to these challenges.

1 January 2021 in Biomaterials
Verified
Journal Article
Closed access
MAMelissa Alvarado-Velez
Melissa Alvarado-Velez
SESyed Faaiz Enam
Syed Faaiz Enam
NMNalini Mehta
Nalini Mehta
JLJohnathan G. Lyon
Johnathan G. Lyon
MLMichelle C. LaPlaca
Michelle C. LaPlaca
RBRavi V. Bellamkonda
Ravi V. Bellamkonda

20 June 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SESyed Faaiz Enam
Syed Faaiz Enam
SKSajidur Rahman Kader
Sajidur Rahman Kader
NBNicholas Bodkin
Nicholas Bodkin
JLJohnathan G. Lyon
Johnathan G. Lyon
MCMark Calhoun
Mark Calhoun
RBRavi Venkat Bellamkonda
Ravi Venkat Bellamkonda
Background: Appropriately modulating inflammation after traumatic brain injury (TBI) may prevent disabilities for the millions of those inflicted annually. In TBI, cellular mediators of inflammation, including macrophages and microglia, possess a range of phenotypes relevant for an immunomodulatory therapeutic approach. It is thought that early phenotypic modulation of these cells will have a cascading healing effect. In fact, an anti-inflammatory, “M2-like” macrophage phenotype after TBI has been associated with neurogenesis, axonal regeneration, and improved white matter integrity (WMI). There already exist clinical trials seeking an M2-like bias through mesenchymal stem/stromal cells (MSCs). However, MSCs do not endogenously synthesize key signals that induce robust M2-like phenotypes such as interleukin-4 (IL-4).Methods: To enrich M2-like macrophages in a clinically relevant manner, we augmented MSCs with synthetic IL-4 mRNA to transiently express IL-4. These IL-4 expressing MSCs (IL-4 MSCs) were characterized for expression and functionality and then delivered in a modified mouse TBI model of closed head injury. Groups were assessed for functional deficits and MR imaging. Brain tissue was analyzed through flow cytometry, multi-plex ELISA, qPCR, histology, and RNA sequencing.Results: We observed that IL-4 MSCs indeed induce a robust M2-like macrophage phenotype and promote anti-inflammatory gene expression after TBI. However, here we demonstrate that acute enrichment of M2-like macrophages did not translate to improved functional or histological outcomes, or improvements in WMI on MR imaging. To further understand whether dysfunctional pathways underlie the lack of therapeutic effect, we report transcriptomic analysis of injured and treated brains. Through this, we discovered that inflammation persists despite acute enrichment of M2-like macrophages in the brain.Conclusion: The results demonstrate that MSCs can be engineered to induce a stronger M2-like macrophage response in vivo. However, they also suggest that acute enrichment of only M2-like macrophages after diffuse TBI cannot orchestrate neurogenesis, axonal regeneration, or improve WMI. Here, we also discuss our modified TBI model and methods to assess severity, behavioral studies, and propose that IL-4 expressing MSCs may also have relevance in other cavitary diseases or in improving biomaterial integration into tissues.

29 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJohnathan G. Lyon
Johnathan G. Lyon
SCSheridan L. Carroll
Sheridan L. Carroll
NMNassir Mokarram
Nassir Mokarram
RBRavi V. Bellamkonda
Ravi V. Bellamkonda
Treatment of neuroepithelial cancers remains a daunting clinical challenge, particularly due to an inability to address rampant invasion deep into eloquent regions of the brain. Given the lack of access, and the dispersed nature of brain tumor cells, we explore the possibility of electric fields inducing directed tumor cell migration. In this study we investigate the properties of populations of brain cancer undergoing electrotaxis, a phenomenon whereby cells are directed to migrate under control of an electrical field. We investigate two cell lines for glioblastoma and medulloblastoma (U87mg & DAOY, respectively), plated as spheroidal aggregates in Matrigel-filled electrotaxis channels, and report opposing electrotactic responses. To further understand electrotactic migration of tumor cells, we performed RNA-sequencing for pathway discovery to identify signaling that is differentially affected by the exposure of direct-current electrical fields. Further, using selective pharmacological inhibition assays, focused on the PI3K/mTOR/AKT signaling axis, we validate whether there is a causal relationship to electrotaxis and these mechanisms of action. We find that U87 mg electrotaxis is abolished under pharmacological inhibition of PI3Kγ, mTOR, AKT and ErbB2 signaling, whereas DAOY cell electrotaxis was not attenuated by these or other pathways evaluated.

1 March 2017 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
NMNalini Mehta
Nalini Mehta
JLJohnathan G. Lyon
Johnathan G. Lyon
KPKetki Patil
Ketki Patil
NMNassir Mokarram
Nassir Mokarram
CKChristine Kim
Christine Kim
RBRavi V. Bellamkonda
Ravi V. Bellamkonda
Treatment of aggressive glioblastoma brain tumors is challenging, largely due to diffusion barriers preventing efficient drug dosing to tumors. To overcome these barriers, bacterial carriers that are actively motile and programmed to migrate and localize to tumor zones were designed. These carriers can induce apoptosis via hypoxia-controlled expression of a tumor suppressor protein p53 and a pro-apoptotic drug, Azurin. In a xenograft model of human glioblastoma in rats, bacterial carrier therapy conferred a significant survival benefit with 19% overall long-term survival of >100 days in treated animals relative to a median survival of 26 days in control untreated animals. Histological and proteomic analyses were performed to elucidate the safety and efficacy of these carriers, showing an absence of systemic toxicity and a restored neural environment in treated responders. In the treated non-responders, proteomic analysis revealed competing mechanisms of pro-apoptotic and drug-resistant activity. This bacterial carrier opens a versatile avenue to overcome diffusion barriers in glioblastoma by virtue of its active motility in extracellular space and can lead to tailored therapies via tumor-specific expression of tumoricidal proteins.